D59.10

Clinical Causes: Autoimmune hemolytic anemia occurs when the immune system produces antibodies that target and destroy red blood cells without an obvious external cause. Specific triggers or associated conditions include: - Certain autoimmune diseases like lupus or rheumatoid arthritis - Recent infections, such as mononucleosis or other viral illnesses - Use of specific medications that can provoke immune responses - Underlying lymphoproliferative disorders, like lymphoma - Hematologic cancers - Sometimes, the exact cause remains unknown, which is referred to as idiopathic AIHA.

Key Symptoms: Individuals with AIHA may experience a variety of symptoms stemming from anemia and the increased destruction of red blood cells. Common signs include: - Fatigue and weakness - Pale or yellowish skin (jaundice) - Shortness of breath, especially during physical activity - Rapid heartbeat (tachycardia) - Dark-colored urine - Fever or chills if related to an infection - Enlarged spleen or liver in some cases - Cold or warm sensations in extremities These symptoms can develop quickly or gradually, depending on the severity and progression of the anemia.

Diagnosis Path: Diagnosing autoimmune hemolytic anemia involves a combination of blood tests and medical evaluations, such as: - Complete blood count (CBC) to assess red blood cell levels - Reticulocyte count to evaluate bone marrow response - Blood smear examination for abnormal red blood cell appearance - Direct antiglobulin test (DAT or Coombs test) to detect immune antibodies attached to red blood cells - Tests to identify underlying conditions or triggers, such as autoimmune diseases or infections - Additional laboratory assessments might include bilirubin levels and lactate dehydrogenase (LDH), which are often elevated in hemolytic anemia. Proper diagnosis is essential for determining the appropriate management approach.

Treatment Protocols: Managing autoimmune hemolytic anemia typically involves medications and supportive care aimed at limiting immune destruction of red blood cells. Common treatments include: - Corticosteroids, such as prednisone, to suppress the immune system - Immunosuppressive drugs in cases where steroids are ineffective or unsuitable - Intravenous immunoglobulin (IVIG) therapy - Blood transfusions to address severe anemia, though cautiously used - Splenectomy, which involves removing the spleen that filters and destroys blood cells, may be considered for chronic or refractory cases - Treatment of underlying causes or associated autoimmune conditions - Monitoring and supportive care to manage symptoms and prevent complications In some cases, newer therapies targeting specific immune pathways are explored, depending on the individual’s health status and response to treatment.